Poster Programme

Poster Session 1
Sunday October 4th
18:00-19:00 | *Grand Gallery*

[P1.01] **Anti-pres responses influence the anti-HBS response in newborns after vaccination with the third generation sci B vac™-vaccine**
S.P.E. Sylvan*[1], K. Madalinski[2], U. Hellstrom[3], *[1]Uppsala County Council, Sweden, [2]National Institute of Health, Poland, [3]Stockholm County Council, Sweden*

[P1.02] **Safety and immunogenicity of oral, live trivlent human-ovine rotavirus reassortant vaccine in Chinese infants**
T. Huang*[1], R.C. Li[1], Y.P. Li[1], X. Zhou[2], Y. Nong[1], *[1]Guangxi Center for Disease Prevention and Control, China, [2]Lanzhou Institute of Biological Products, China*

[P1.03] **In vivo engineering of a cellular immune response by coadministration of LIGHT as a genetic adjuvant with a DNA immunogen**
S. Pouyanfard*[1], T. Bamdad[1], M. Parsania[1], H. Hashemi[1], M. Gorgian Mohamadi[1], *[1]Tarbiat Modares University, Iran*

[P1.04] **A pilot study on intradermal vaccination of Japanese rabies vaccine for pre-exposure immunization**
A. Nishizono*[1], S. Shiota[1], P. Khowplod[2], K. Ahmed[1], *[1]Oita University, Japan, [2]Thai red Cross Society, Thailand*

[P1.06] **Hospital-based, febrile illnesses surveillance and the role of *salmonella* infections in Agogo, Ghana**
F. Marks*[1], Y. Adu-Sarkodie[2,3], N. Sarpong[2], F. Huenger[2], W. Loag[4], M.O. Favorov[1], *[1]International Vaccine Institute, South Korea, [2]Kumasi Centre for Collaborative Research in Tropical Medicine, Ghana, [3]Kwame Nkrumah University for Science and Technology, Ghana, [4]Bernhard Nocht Institute for Tropical Medicine, Germany*

[P1.08] **IL-7 and IL-15 promote long-lasting T CD4$^+$ cell memory against BCG**
J. Agrewala*[1], V. Singh[1], *[1]Institute of Microbial Technology, India*

[P1.09] **Predictors of childhood vaccination uptake: A cross-sectional study in Greece**
K. Danis*[1], T. Georgakopoulou[2], T. Stavrou[3], D. Laggas[1], T. Panagiotopoulos[1], *[1]National School of Public Health, Greece, [2]Hellenic Centre for Disease Control and Preventio, Greece, [3]Ministry of Health, Greece*

[P1.10] **Waning immunity and booster responses in adolescents vaccinated with plasma-derived or recombinant hepatitis B vaccine**
C.C. Lin*[1,3], Y.L. Huang[3], C.T. Shih[1], *[1]Fooyin University Hospital, Taiwan, [2]Fooyin University, Taiwan, [3]Kaohsiung Medical University, Taiwan*

[P1.11] **Potential treatment of human papillomavirus associated tumor using recombinant inactive-E7 lipoproteins**
C.Y. Huang*, J.J.W. Chen, L.S. Chang, T.Y. Huang, S.J. Liu, C.H. Leng, *National Health Research Institutes, Taiwan*

[P1.13] **Vaccine development against enterovirus 71 using live attenuated *bordetella pertussis* as a nasal delivery system**
W.X. Khong*, S. Alonso, *National University of Singapore, Singapore*

[P1.14] **Projecting the efficacy of RotaTeq™ against rotavirus related hospitalizations and death in seven Asian countries**
A.C. El Khoury*, T.C. Mast, M. Ciarlet, L. Markson, M. Goveia, *Merck & Co, Inc, USA*

[P1.15] **Single-dose primary vaccination with AS03$_A$-adjuvanted prepandemic H5N1 influenza vaccine is sufficient to induce strong, rapid and broad immune response to booster vaccination after 12 months**
T. F. Schwarz[1], T. Horacek[2], M. Knuf[3], H.G. Dammann[4],
Paul Gillard*[,5], Wolfgang Jilg[6] et al, *[1]Stiftung Juliusspital, Würzburg, [2]Medical Practice Witten, [3]Johannes Gutenberg-University, Mainz, [4]Clinical Research Institute Schwerin, Germany, [5]GlaxoSmithKline Biologicals, Belgium, [6]University Regensburg, Germany*

[P1.16] **Effect of rhinitis on seroresponse to measles vaccine given by aerosol or injected routes**
A. Dilraj*[1], J.V. Bennett[2], F.T. Cutts[3], J.F. de Castro[4], *[1]Medical Research Council, South Africa, [2]Consultant, USA, [3]London School of Hygiene and Tropical Medicine, UK, [4]Instituto Nacional de Salud Publica, Mexico*

[P1.17] **Safety and immunogenicity of adjuvanted and non-adjuvanted influenza A (H5N1) vaccine in children**
T. Chotpitayasunondh[1], C. Pancharoen[2], S. Pepin[3], Y. Hutagalung*[4], *[1]Queen Sirikit National Institute of Child Health, Thailand, [2]Chulalongkorn Hospital, Thailand, [3]Sanofipasteur, France, [4]Sanofipasteur, Singapore*

[P1.18] **Expression library immunization screening of burkholderia mallei for subunit vaccine candidates**
D.M. Estes*[1], A. Deeraska[1], B.M. Judy[1], G.M. Whitlock[1], K. Sykes[2], A. Torres[1], *[1]University of Texas Medical Branch, USA, [2]Arizona State University, USA*

[P1.19] **Development of a second-generation vaccine against dengue**
D. Nico, R.M.C. Godinho, A.C.E.R. Berbel, L. Arruda, C.B. Palatnik-de-Sousa*, *Universidade Federal do Rio de Janeiro (UFRJ), Brazil*

[P1.20] **Oral MucoRice-CTB induces toxin-protective serum antibodies but does not influence natural intestinal immunity in nonhuman primates**
Y. Yuki*[1], T. Nochi[1], Y. Katakai[2], H. Shibata[3], D. Tokuhara[1], M. Mejima[1], *[1]The University of Tokyo, Japan, [2]Corporation for Production and Research of Laboratory Primates, Japan, [3]Tsukuba Primate Research Center, Japan*

[P1.21] **A patient safety issue: Mandatory influenza vaccination for health care workers**
S. Wicker*, H.F. Rabenau, *University Hospital Frankfurt, Germany*

[P1.22] **Immunoinformatic-discovered *mycobacterium tuberculosis* T-cell epitope vaccine candidates are validated in HLA transgenic mice**
L. Moise[1,2], J. Desrosiers[1], R. Tassone[1], W. Martin[1], A. De Groot*[1,2], H. Kornfeld[3], *[1]EpiVax, Inc, USA, [2]University of Rhode Island, USA, [3]University of Massachusetts Medical Center, USA*

[P1.23] ***Staphylococcus aureus* vaccines: Protection depends on the bacterial strain and the pre-immune state of the host**
M. Lafrance[1], M. Rivest[1], P. Lacasse[3], J. Perez-Casal[2], F. Malouin[1], B. Talbot*[1], *[1]Université de Sherbrooke, Canada, [2]Vaccine and Infectious Disease Organisation, Canada, [3]Agriculture and Agri-Food, Canada*

[P1.24] **The administration dosage of influenza vaccine for infants: Is it sufficient in Japan?**
T. Tanaka*, *Hitachi, Ltd. Mito General Hospital, Japan, Mito Kyodo General Hospital, Japan*

[P1.25] **Identification of naturally processed HLA-A11-restricted CTL epitopes derived from HPV type 18**
H.W. Chen[1,2], C.H. Leng[1], H.Y. Liu*[1], W.F. Cheng[3], Y.W. Chang[1], P.Y. Wu[4], *[1]Vaccine Research and Development Center, Taiwan, [2]China Medical University, Taiwan, [3]National Taiwan University, Taiwan, [4]Academia Sinica, Taiwan*

[P1.26] **Infection with a highly attenuated strain of *bordetella pertussis* in mice provides cross-protection against lethal challenge with influenza a viruses by dampening the cytokine storm**
R. Li, A. Lim*, T. Narasaraju, M.C. Phoon, V.T. Chow, S. Alonso, *National University of Singapore, Singapore*

[P1.27] **Immunogenicity of a 10-valent pneumococcal non-typeable *haemophilus influenzae* protein D-conjugate vaccine (PHID-CV) co-administered with routine paediatric vaccines in asian infants**
N. Bermal*[1], T.Y. Lin[2], L.M. Huang[3], S. Gatchalian[4], H. Tang[4], L. Schuerman[4], *[1]Research Institute for Tropical Medicine, Philippines, [2]Chang Gung Memorial Hospital, Taiwan, [3]National Taiwan University Hospital, Taiwan, [4]GlaxoSmithKline Biologicals, Belgium*

[P1.28] **Burden of dengue fever in Eastern Kolkata, India: Data from a prospective community based study**
S. Kanungo*[1], D.A.C.L. Amarasinghe[2], D. Sur[1], B. Manna[1], S. Chatterjee[1], P. Sadhukhan[1], *[1]Indian Council of Medical Research, India, [2]International Vaccine Institute, South Korea*

[P1.29] **Recombinant influenza A N1 neuraminidase induces cross-protective immunity against H5N1 viruses**
P.L. Hervé, V. Lorin, N. Noulin, F. Reynard, G. Jouvion, N. Escriou*, *Institut Pasteur, France*

[P1.30] **Immunogenicity study of rabies post-exposure vaccination after switching schedule from intramuscular regimen to intradermal regimen**
T. Tantawichien*[1], P. Shantavasinkul[1], P. Khawplod[1], T. Tantawichien[1,2], *[1]Queen Saovabha Memorial Institute, Thailand, [2]Chulalongkorn University, Thailand*

[P1.31] **Th1 and Th2 type epitopes cocktail, as a DNA vaccine against *helicobacter pylori***
T. I. Carvalho*[1], M. Roxo-Rosa[1], C. R. C. Calado[1], *[1]Universidade Católica Portuguesa, Portugal*

[P1.32] **Expression of fusion protein of human respiratory syncytial virus from chimeric rubella virus vectors**
K.N. Hsiao*, P. Chong, Y.H. Chow, *National Health Research Institute, Taiwan*

[P1.33] **HIV-1 gag-virus-like particles induce in vitro and in vivo stimulation of NK cell and T cell immune responses**
M.O. Chang*, T. Suzuki, H. Suzuki, H. Takaku, *Chiba Institute of Technology, Japan*

[P1.34] **Rapid development of adenovirus-based vaccines for biosafety level 4 viruses**
M. Sahib*[1,2], R. Flick[3], H. Feldmann[3], G. Kobinger[1,2], *[1]University of Manitoba, Canada, [2]National Microbiology Laboratory/Public Health Agency of Canada, Canada, [3]Bioprotection Systems Corporation, USA, [4]Rocky Mountain Laboratories, USA*

[P1.35] **Application of electroporation in the development of multivalent DNA vaccines**
B.D. Livingston*, D. Hannaman, *Ichor Medical Systems, USA*

[P1.36] **Mechanisms of *anisakis*-induced contact dermatitis and associated systemic sensitization**
N.E. Nieuwenhuizen[1], D.R. Herbert[1], M.F. Jeebhay[1], F. Brombacher[1], A.L. Lopata*[1,2], *[1]University of Cape Town, South Africa, [2]RMIT University, Australia*

[P1.37] **Immunogenicity and safety of an investigational hepatitis B vaccine: Experience in 2,500 subjects**
S.A. Halperin[1], M.L. Pecoraro[2], J.T. Martin*[2], *[1]Dalhousie University, Canada, [2]Dynavax Technologies, USA*

[P1.38] **Phase II clinical trials of oral therapeutic hepatitis vaccine in patients with chronic hepatitis B and C**
A.S. Bourinbaiar, *Immunitor USA Inc, USA*

[P1.39] **An evaluation of HT29 cells for plaque formation with *apy* mutant of *shigella flexneri* 2A construct: Towards development of live attenuated *shigella* vaccine**
M. Nisha*[1], M.Z. Salleh[3], L. Hut Yee[2], M. Ravichandran[4], K. Kirnpal[1], *[1]Universiti Sains Malaysia (USM), Malaysia, [2]Universiti Teknologi Mara (UiTM), Malaysia, [3]Universiti AIMST University(AIMST), Malaysia*

[P1.40] **SopB of Salmonella enterica serovar typhimurium is a potential DNA vaccine candidate in conjugation with live attenuated bacteria**
A.G. Nagarajan*, D. Chakravortty, *Indian Institute of Science, India*

[P1.41] **Mass spectrometry analysis of HIV-1 envelope proteins**
A.N. Galkin, E.Y. Filinova*, A.I. Soloviev, A.B. Bychenko, N.B. Polyakov, V.N. Nikiforov, *Advanced Biomedical Research Laboratory, Russian Federation*

[P1.42] **Immunogenicity of a recombinant *mycobacterium bovis* bacille Calmette–Guèrin expressing T and B cell epitopes of *M. tuberculosis* antigens**
N.M. Norazmi*[1], R. Mohamud[1], R. Kadir[1], M. Azlan[1], N. Olivares[2], A. Vila[2], *[1]Universiti Sains Malaysia, Malaysia, [2]Instituto Finlay, Cuba*

[P1.43] **PLGA nanospheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN: Preparation and in vitro characterization**
S.A. Sajadi Tabassi*, M. Tafaghodi, N. Amiri, *University of Medical Sciences, Iran*

[P1.44] **Evaluation of immunogenicity of cross-genotypic liposome encapsulation of hepatitis E virus open reading frame 2 protein/DNA components of genotypes 1 and 4 in mice**
S. Shrivastava*, K. Lole, V. Arankalle, *National Institute of Virology, India*

[P1.45] **Development of combination vaccine against hepatitis B and hepatitis E viruses: A liposome encapsulation approach**
S. Shrivastava*, K. Lole, A. Tripathy, V. Arankalle, *National Institute of Virology, India*

[P1.46] **Assessing herd immunity in the elderly following the vaccination of school children with live, attenuated trivalent influenza vaccine (LAIV): A county-level analysis**
A.M. McBean*[1], H.F. Hull[2], D.S. Caldwell[1], H. O'Connor[1], *[1]University of Minnesota, USA, [2]H.F. Hull & Associates, USA*

[P1.47] **Weighing benefits and risks of universal vaccination against illness from a pandemic low-profile influenza virus: Obtain informed consent in preventive vaccination programs based on individualized assumptions**
J. Mau, *Heinrich Heine University Hospital, Germany*

[P1.48] **RetroVLP-based vaccines: Technology and application to Hepatitis C**
C. Dalba*, P. Garrone, A.C. Fluckiger, I. du Chene, J. Mancip, P. Mangeot, et al, *EPIXIS S.A., France*

[P1.49] **Pneumococcal vaccination and risk of myocardial infarction and stroke**
H.F. Tseng*, J. Slezak, V.P. Quinn, S.J. Jacobsen, *Kaiser Permanente, USA*

[P1.50] **Production of the recombinant dermatophagoides farinae paramyosin Blo t 11 and its immunodominant peptide in insect cells**
N. Malainual[1], J. Rabablert*[2], S. Tiewchareon[1], D. Tongdee[2], R. Pipatchaipaisan[2], *[1]Mahidol University, Thailand, [2]Silpakorn University, Thailand*

Poster Programme

Poster Session 2
Monday October 5th
12:30-13:40 | *Grand Gallery*

[P2.02] **Multifront assault on antigen presentation by Japanese encephalitis virus subverts $CD8^+$ T cell responses**
Y.W. Han*, M.M. Rahman, S.J. Kim, E. Uyanga, S.B. Kim, S.K. Eo, *Chonbuk National University, South Korea*

[P2.03] **Immune responses induced by prime-boost immunization using DNA vaccine, adenovirus, and vaccinia virus expressing E protein of dengue virus**
Y.W. Han*[1], J.H. Kim[1], M.M. Rahman[1], S.J. Kim[1], E. Uyanga[1], S.K. Eo[1], [1]*Chonbuk National University, South Korea*

[P2.04] **Evaluation of the effectiveness of GP96 rich lysate as a vaccine against infection with *Salmonella typhimurium***
N.H. Jazani*, S. Shahabi, R Ghareaghaji, *Urmia University of Medical Sciences, Iran*

[P2.05] **Genetic fusion of heat shock protein 70 (HSP70) to a mycobacterial antigen enhances the antigen-specific T cell responses**
T. Uto*, M. Uchijima, Y. Koide, T. Suda, K. Chida, H. Nakamura, *Hamamatsu University, Japan*

[P2.06] **Vaccination and allergy: The right choice of the adjuvant system as well as the time point of vaccination might influence allergy development**
A. Wagner*[1], B. Winkler[1], I. Schabussova[1], C. Herzog[2], U. Wiedermann[1], [1]*Medical University of Vienna, Austria,* [2]*Berna Biotech Crucell, Switzerland*

[P2.07] **BCG immunisation induces multifunctional Th1 cells in the spleen & lungs which preferentially expand and correlate with active immunity to a *mycobacterium bovis* challenge**
D.A. Kaveh, R.G. Hewinson, P.J. Hogarth*, *Veterinary Laboratories Agency, UK*

[P2.08] **The immunomodulatory effects of astragalus polysaccharides on immunosuppressive dogs**
H. Qiu*[1], J. Xu[1], F. Liu[2], X. Zhu[2], J. Zhao[1], Y. Zhang[3], [1]*China Agricultural University, China,* [2]*Beijing University of Agriculture, China,* [3]*Beijing Medicass Biotechnologies, Co. Ltd., China*

[P2.09] **T-cell responses to H5 and H1N1 antigens after vaccination with an adjuvanted or non-adjuvanted H5N1 vaccine**
M. Denis[1], F. Janet-Blaudez[1], C. Caillet[1], M. Dupuy[1], A. De Montfort[1], Y. Hutagalung*[2], [1]*Sanofipasteur, France,* [2]*Sanofipasteur, Singapore*

[P2.10] **$AS03_A$-adjuvanted pandemic influenza vaccine protects against heterologous H5N1 challenge in the pig model**
A. De Vleeschauwer[1], B. Baras[2], C.S. Kyriakis[1], S.L. Giannini*[2], S. Mossman[2], K. Van Reeth[1], [1]*Ghent University, Belgium,* [2]*GlaxoSmithKline Biologicals, Belgium*

[P2.11] **Molecular Enteropathogenesis of ctxA and rtxC genes of *V. cholerae* O139 in rabbit model**
T. GimCheong*, *University Sains Malaysia, Malaysia,* [2]*AIMST University, Malaysia,* [3]*Management & Science University, Malaysia*

[P2.12] **Comparison of the immune protection induced by the Chinese attenuated eiav vaccine $eiav_{FDDV12}$ and its infectious molecular clone**
J. Ma*[1,2], N. Shi[1], Y. Lin[1], R. Shen[1], X. Kong[1], J. Zhou[1], [1]*Harbin Veterinary Research Institute, China,* [2]*Northeast Forestry University, China*

[P2.13] **Antibody response to allelic variants of 19-kDa fragment of MSP1 - recognition of variant and protection associated with ethnicity in Assam, India**
S. Baruah*, S.D. Lourembam, *Tezpur University, India*

[P2.14] **Reduced cellular response following immunization with multivalent DNA vaccines against avian influenza H5N1 suggests antigenic interference**
A. Patel*[1,2], M. Gray[2], T. Taylor[2], K. Tran[2], D. Kobasa[1,2], G. Kobinger[1,2], *[1]University of Manitoba, Canada, [2]National Microbiology Laboratory, Public Health Agency of Canada, Canada*

[P2.15] **Immunocomplexes of IL-2 and anti-IL-2 mAb as novel perspective tool for cancer immunotherapy**
J. Tomala*, H. Chmelova, B. Rihova, M. Kovar, *Institute of Microbiology, V.VI, Czech Republic*

[P2.16] **Modulation of immune responses by immunocomplexes of IL-2 and different anti-IL-2 mAbs**
M. Kovar*, J. Tomala, H. Chmelova, B. Rihova, *Institute of Microbiology, Czech Republic*

[P2.18] **A non-adapted dengue virus strain as a model for acute lethal dengue infection and vascular leakage syndrome in mice upon peripheral administration**
T. Kai Xin Grace*, A. Sylvie, *National University of Singapore, Singapore*

Poster Programme

Poster Session 3
Tuesday October 6th
12:10-13:20 | *Grand Gallery*

[P3.01] **Preclinical investigation of synthetic lysine lipopeptides as adjuvants for desired (Th1&Th2) immune responses**
T. Sidiq*, P. Suden, A. Khajuria, T. Ismail, H.S. Kumar, S.C. Taneja, *Indian Institute of Integrative Medicine, India*

[P3.02] **Preparation and optimization of chitosan nanospheres containing adjuvanted influenza vaccine for nasal delivery**
S. Dehghan*[1], M. Tafaghodi[1], M. Tavassoti Kheiri[2], *[1]Mashhad School of Pharmacy and Pharmaceutical Research Center, Iran, [2]Influenza Research Center, Iran*

[P3.03] **IgA and IgG levels in lung and serum after oral immunization with BCG encapsulated in alginate microspheres**
S. Ajdary*[1], M. Hosseini[1], F. Dobakhti[2], *[1]Pasteur Institute of Iran, Iran, [2]Zanjan University of Medical Sciences, Iran*

[P3.04] **Attenuated *salmonella typhimurium* expressing swine interferon-a shows antiviral activity and alleviates clinical sign induced transmissible gastroenteritis virus infection in suckling pigs**
S.J. Kim*, S.B. Kim, Y.W. Han, M.M. Rahman, E. Uyanga, S.K. Eo, *Chonbuk National University, South Korea*

[P3.05] **Orally administered recombinant *lactococcus lactis* induces protection against H5N1 virus challenge in mice**
H. Lei*, Y. Xu, *Shanghai Jiao Tong University, China*

[P3.07] **The immunomodulatory properties of *lactobacillus plantarum* are dependent on CD14, NOD2 and MAPK**
P. Rigaux[1], E. Adam[1], C. Bouillot[1], J.G. Magalhaes[2], D. Philpott[2], A. Jacquet*[1,3], *[1]Universite Libre de Bruxelles, Belgium, [2]University of Toronto, Canada, [3]Chulalongkorn University, Thailand*

[P3.08] **The recombinant attenuated coxsackievirus as a viral vector for vaccination or gene therapy**
K.B. Park*, D.S. Kim, Y.J. Cho, J.H. Nam, *The Catholic University of Korea, South Korea*

[P3.10] **Transcutaneous immunization by chitosan complex-patch based DNA vaccines is effective vaccination against Japanese encephalitis virus infection**
C.J. Wu, H.N. Huang*, *National Taiwan Ocean University, Taiwan*

[P3.11] **Antigen cross-presenting effect of gas-producing liposomes**
J. Chen*, H. Huang, Y. Yang, Q. Ding, W. Ding, Y. Xu, *Shanghai Jiao Tong University, China*

[P3.12] **Functional reconstitution liposomes with MHC-II rich lipid rafts**
D. Qian*, Y.H. Xu, *Shanghai Jiao Tong University, China*

[P3.13] **Self-assembled nanoparticles made of dextrin and mannan: Production, characterization, biocompatibility and potential applications**
F.M Gama*, S.M Ferreira, C. Gonçalves, *Minho University, Portugal*

[P3.14] **Lipid microparticles: Novel immunoadjuvant for mucosal immunization**
S.S. Deodia*[1], G. Mittal[2], A. Bhatnagar[2], V.K. Kashyap[3], N.K. Jain[1], *[1]Dr. H. S. Gour University, India, [2]Nuclear Medicine Division, India, [3]National Institute of Biologicals, India*

[P3.15] **Preclinical study to access the immunogenicity and safety of recombinant HBsAg vaccine with potent adjuvant candidate (immunoside)**
A. Khajuria*, T. Sidiq, P. Suden, R. Sharma, A. Kaul, S. Singh, et al *Indian Institute of Integrative Medicine, India*

[P3.16] **Modulation of immune responses by targeting macrophage and T & B- cell activation**
T. Sidiq*, P. Suden, A. Khajuria, K.A. Suri, N.K. Satti, S.C. Taneja, *Indian Institute of Integrative Medicine, India*

[P3.17] **Improved intradermal immunization using microneedle patches coated with influenza VLPs**
Y.C. Kim*[1], F.S. Quan[2], J.M. Song[2], R.W. Compans[2], S.M. Kang[2], M.R. Prausnitz[1], [1]*Georgia Institute of Technology, USA,* [2]*Emory University School of Medicine, USA*

[P3.18] **Advantages of intranasal vaccination and considerations on device selection**
D. Marx, *Ing. Erich Pfeiffer GmbH, Germany*

[P3.19] **Modulation of immunity against herpes simplex virus via mucosal genetic co-transfer of DNA vaccine with β_2-adrenergic agonist**
S.B. Kim*, Y.W. Han, M.M. Rahman, S.J. Kim, E. Uyanga, S.K. Eo, *Chonbuk National University, South Korea*

[P3.20] **Protective immunity enhanced by genetic co-transfer of CCR7 ligands and prolonged survival against virulent challenge of pseudorabies virus**
Y.W. Han*, M.M. Rahman, S.J. Kim, E. Uyanga, S.B. Kim, S.K. Eo, *Chonbuk National University, South Korea*

[P3.21] **Modulation of the nature of protective immunity by genetic co-transfer of plasmid DNA encoding chemokine with DNA vaccine against pseudorabies virus**
Y.W. Han*, M.M. Rahman, S.J. Kim, E. Uyanga, S.B. Kim, S.K. Eo, *Chonbuk National University, South Korea*

[P3.22] **Elevation of the immunity of piglets to Mycoplasma vaccine with the fusion gene for pig IL-4 and IL-6 encapsulated in chitosan nanoparticles**
X. Yang*, J.L. Chen, H. Zhang, X.P. Wan, L. Cai, R. Gao, *Sichuan University, China*

[P3.23] ***Bordetella bronchiseptica* aroA mutant as a live vaccine vehicle for heterologous porcine circovirus type 2 major capsid protein expression**
T. Kim*, J. Lee, B. Lee, *Chonnam National University, South Korea*

[P3.24] **Evaluation of the inactivated H9N2 avian influenza vaccine on viral replication and shedding in broiler chickens using TaqMan real time PCR**
H.T. Tavakkoli, K.A. Asasi*, A.M. Mohammadi, *Shiraz University, Iran*

[P3.25] **The effect of infectious bronchitis live vaccine (H120) on LPAI H9N2 replication and shedding in broiler chickens**
H.T. Tavakkoli, K.A. Asasi, A.M. Mohammadi*, *Shiraz University, Iran*

[P3.26] **Codon-optimized expression of fish iridovirus capsid protein in yeast and its application as a vaccine candidate**
T. Kim*, J. Lee, *Chonnam National University, South Korea*

[P3.27] **Evaluation the quality of oil-emulsion avian influenza subgroup H9N2 vaccines in in-vitro**
Z. Rajabi*, H. Tayefi-Nasrabadi, A.B. Syofi-Khojin, *University of Tabriz, Iran*

[P3.28] **Hypervaccination as a new efficient strategy for eradication of classical swine fever (CSF)**
V.A. Sergeyev*, O.V. Sergeyev, *The D.Ivanovski Institute of Virology, Russian Federation*

[P3.29] **A delivery vehicle for oral vaccination of poultry**
W.I. Muir*[1], G. Vandenberg[2], T.A. Scott[3], [1]*University of Sydney, Australia,* [2]*PerOs Systems Technology, Canada,* [3]*Provimi Research and Innovation, Belgium*

[P3.30] **Development of engineering vaccines based on protective antigens 45W-4B and TSOL18 from *Taenia solium* oncosphere**
X. Cai*, X. Luo, Y. Zheng, *Lanzhou Veterinary Research Institute, China*